Around him the newsroom of the New York Sentinel, a weekly newspaper positioned editorially somewhere between the late, lamented New York Observer and the Village Voice, was in final Sunday countdown, with the Monday edition about to be put to bed. The technology was state of the art, and the room flickered with computer screens, blue pages that gave the tan walls an eerie cast. Composition, spell-checking, everything, was done by thinking machines, and the reporters, thirteen on this floor, were mostly in their late twenties and early thirties and universally underpaid. The early morning room was bustling, though it felt to Stone like the end of time. Nobody was paying any attention to him but that was normal: everybody was doing their own thing. Besides, nobody else realized he'd just had a major piece killed at the last minute. Now he felt as though he were frozen in place: in this room, in this job, in this life. The book he had almost finished was going to change a lot of things. It would be the first major explication of stem cell technology for general readers. Stem cells were going to revolutionize everything we knew about medicine and the research was going further than anyone could have dreamed. The possibility of reversing organ degeneration, even extending life, was hovering right out there, just at humankind's fingertips. It cried out for a major book. He had read everything that had made its way into the medical journals, but the study that was furthest along was privately funded and now cloaked in secrecy. It was at the Gerex Corporation, whose head researcher was a Dutch genius named Karl Van de Vliet. The company had been bankrolled by the medical mogul Winston Bartlett after Van de Vliet lost his funding at Stanford. Winston Bartlett, of all people . . . but that was another story. Thirteen months earlier, the Gerex Corporation had trolled for volunteers on the National Institutes of Health Web site, referring to a pending "special study." The notice suggested the study might be using stem cell technology in some fashion. If that study was what Stone Aimes thought it was, it would be the first to use stem cells in stage-three clinical trials. Nobody else was even close. Karl Van de Vliet was the ball game. Unfortunately, however, his study was being held in an atmosphere of military-like secrecy. Why? Even the identities of the participants in the trials were like a state secret. Since Winston Bartlett owned Gerex, it surely had been ordered by him. You had to wonder what that was all about. Whatever the reason, Stone Aimes knew that in order to finish his book with the latest information he had to get to Van de Vliet. But Bartlett had forbidden any interviews, and Gerex's clinic, called the Dorian Institute, was off-limits to the public and reportedly guarded with serious security. But, he thought, perhaps he had just come up with an idea of how to get around that. . . .